One of the most distinctive aspects of Cure SMA’s research program is the SMA Industry Collaboration. Established in 2016, the SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, Cure SMA, and other nonprofit organizations, to share information, ideas, and data. The SMA Industry Collaboration works together to address scientific, clinical, and regulatory topics that are critical to advancing drug development in spinal muscular atrophy (SMA) and will benefit the broader SMA community. It is currently comprised of our partners at Biogen, Genentech/Roche Pharmaceuticals, Scholar Rock, Novartis Gene Therapies, Biohaven Pharmaceuticals, Epirium Bio, and SMA Europe.
Through the SMA Industry Collaboration, we fund research to ensure that effective, safe treatments can progress through clinical trials quickly and gain approval from the U.S. Food and Drug Administration (FDA) and international regulators. Our research also ensures these treatments address the unmet needs of the SMA community, and that the community’s priorities and goals are incorporated into the development, review and approval of therapies. The SMA Industry Collaboration is also conducting research to understand and identify disparities and perceived gaps in SMA care, treatment, and clinical trial research access. With this insight, we will create initiatives to increase access to SMA care and clinical research for all members of the SMA community.